Extended-release ranolazine: Critical evaluation of its use in stable angina

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 535-539

  Truffa, Adriano A M ^a   Newby, L Kristin ^a   Melloni, Chiara ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angina; Coronary heart disease; Ranolazine; Treatment

Indexed keywords

ACETANILIDE DERIVATIVE; CARDIOVASCULAR AGENT; PIPERAZINE DERIVATIVE; RANOLAZINE;

ANIMAL; DELAYED RELEASE FORMULATION; HUMAN; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

ACETANILIDES; ANGINA, STABLE; ANIMALS; CARDIOVASCULAR AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; PIPERAZINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84855986875     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S15560     Document Type: Review

References (28)

1. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther. 2010;27(4):193-201.
2. Trujillo TC, Dobesh PP. Traditional management of chronic stable angina. Pharmacotherapy. 2007;27(12):1677-1692.
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
4. Vadnais DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag. 2010;6:517-530.
5. Norton C, Georgiopoulou V, Kalogeropoulos A, Butler J. Chronic stable angina: Pathophysiology and innovations in treatment. J Cardiovasc Med (Hagerstown). 2011;12(3):218-219.
6. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
7. Melloni C, Newby LK. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther. 2008;6(1):9-16.
8. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006;151(6):e1181-e1189.
9. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566-575.
10. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264-2274.
11. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350(9076):461-468.
12. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15):1503-1516.
13. Newby LK, Peterson ED. Does ranolazine have a place in the treatment of acute coronary syndromes? JAMA. 2007;297(16):1823-1825.
14. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775-1783.
15. Dobesh PP, Trujillo TC. Ranolazine: A new option in the management of chronic stable angina. Pharmacotherapy. 2007;27(12): 1659-1676.
16. Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak beta1-and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 2001;363(4):464-471.
17. Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol. 1993;21(6):869-873.
18. Zhao G, Walsh E, Shryock JC, et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011; 57(6):639-647.
19. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8): 1375-1382.
20. Estacion M, Waxman SG, Dib-Hajj SD. Effects of ranolazine on wildtype and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain. 2010;6:35.
21. Siddiqui MA, Keam SJ. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs. 2006;66(5):693-710.
22. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA. 2004;291(3):309-316.
23. US Food and Drug Administration. Available from: http://www.fda. gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf. Accessed April 4, 2007.
24. Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR, Liu Y. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(14):1418-1430.
25. Herron WJ, Eadie J, Penman AD. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatographyatmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring. J Chromatogr A. 1995;712(1):55-60.
26. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 2005;78(3):288-297.
27. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2(4):344-353.
28. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on diseasespecific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1(2):107-115.